Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $94 to $100.
July 22, 2024 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Intra-Cellular Therapies and raises the price target from $94 to $100.
The raised price target and maintained Buy rating from a reputable analyst are likely to positively influence investor sentiment and drive short-term price appreciation for ITCI.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100